Business
Imfinzi improved EFS in resectable lung cancer
Imfinzi improved EFS in resectable lung cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n \n \n \n 9 March 2023 07:00 GMT\n \n \n \n \n \n \n Imfinzi\n \n \n significantly improved event-free survival in AEGEAN\n \n \n \n \n Phase III trial for patients with resectable non-small cell lung cancer\n \n \n \n \n \n \n \n \n \n Results showed that Imfinzi-based treatment before and after surgery significantly increased the time patients live without recurrence or progression events\n \n \n \n \n \n \n Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo- controlled trial showed that treatment with AstraZeneca's Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC).\n \n \n \n \n \n Results from the final pathologic complete response (pCR)\n and major pathologic response (mPR) analyses were consistent with\n \n previously announced\n \n positive results.\n The trial will continue as planned to assess key secondary endpoints including disease-free survival (DFS) and overall survival (OS).\n \n \n \n \n \n Each year there are an estimated 2.2 million people diagnosed with lung cancer globally with 80-85% of patients diagnosed with NSCLC, the most common form of lung cancer\n .1-3 Approximately 25-30% of all patients with NSCLC are diagnosed early enough to have surgery with curative intent.4-5 However, only around 56-65% of patients with Stage II disease will survive for five years.6 This decreases to 41% for patients with Stage IIIA and 24% for patients with Stage IIIB disease, reflecting a high unmet\n medical need\n .6\n \n \n \n \n \n John V. Heymach, MD, PhD. Professor and Chair Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, said:\n \"\n Treating patients early with durvalumab both before and after surgery delivers a significant and clinically meaningful benefit in resectable non-small cell lung cancer, where new options are urgently needed to offer patients the best chance of long-term survival. The AEGEAN results provide compelling evidence that this novel durva...